{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T19:32:00Z","timestamp":1778959920402,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10072-025-08135-5","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T03:23:02Z","timestamp":1743304982000},"page":"3085-3095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling Gaps and Demographic Influences in Alzheimer\u2019s Therapy: A Data-Centric Study of FDA-Approved Late-Phase Clinical Trials"],"prefix":"10.1007","volume":"46","author":[{"given":"Vaishnavi Milind","family":"Kalokhe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Simran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aftab","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fathima","family":"Musthafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishal Sachin","family":"Gangawane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev Singh","family":"Raghuvanshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0723-4363","authenticated-orcid":false,"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"8135_CR1","doi-asserted-by":"publisher","unstructured":"Merkatz RB, Temple R, Subel S, Feiden K, Kessler D (1993) Women in clinical trials of new drugs-a change in food and drug administration policy. NEJM. https:\/\/doi.org\/10.1056\/NEJM199307223290429","DOI":"10.1056\/NEJM199307223290429"},{"key":"8135_CR2","doi-asserted-by":"crossref","unstructured":"Labots G, Jones A, de Visser SJ, Rissmann R, Burggraaf J (2018) Gender differences in clinical registration trials: is there a real problem? Br J Clin Pharmacol 84(4):700\u2013707","DOI":"10.1111\/bcp.13497"},{"key":"8135_CR3","doi-asserted-by":"publisher","unstructured":"Waggoner MR, Lyerly AD (2022) Clinical trials in pregnancy and the \u201cshadows of thalidomide\u201d: Revisiting the legacy of Frances Kelsey. Contemp Clin Trials\u00a0119:106806.\u00a0https:\/\/doi.org\/10.1016\/j.cct.2022.106806","DOI":"10.1016\/j.cct.2022.106806"},{"key":"8135_CR4","unstructured":"9 Health Issues Every Woman Should Understand. https:\/\/www.nm.org\/healthbeat\/healthy-tips\/9-health-issues-every-woman-should-understand. Accessed 25 Oct 2024"},{"key":"8135_CR5","unstructured":"WHO (2024) The Global Health Observatory Explore a world of health data. https:\/\/www.who.int\/data\/gho\/data\/themes\/global-dementia-observatory-gdo. Accessed 18 Oct 2024"},{"key":"8135_CR6","unstructured":"Association A. Women and Alzheimer\u2019s. https:\/\/www.alz.org\/alzheimers-dementia\/what-is-alzheimers\/women-and-alzheimer-s. Accessed 10 Oct 2024"},{"key":"8135_CR7","doi-asserted-by":"publisher","unstructured":"Liu KA, Dipietro Mager NA (2016) Women\u2019s involvement in clinical trials: historical perspective and future implications. Pharm Pract. https:\/\/doi.org\/10.18549\/PharmPract.2016.01.708","DOI":"10.18549\/PharmPract.2016.01.708"},{"key":"8135_CR8","doi-asserted-by":"publisher","unstructured":"Sosinsky AZ, Rich-Edwards JW, Wiley A, Wright K, Spagnolo PA, Joffe H (2022) Enrollment of female participants in United States drug and device phase 1\u20133 clinical trials between 2016 and 2019. Contemp Clin Trials. https:\/\/doi.org\/10.1016\/j.cct.2022.106718","DOI":"10.1016\/j.cct.2022.106718"},{"key":"8135_CR9","doi-asserted-by":"publisher","unstructured":"Pinho-Gomes A-C, Gong J, Harris K, M Woodward, Cheryl C (2022) Dementia clinical trials over the past decade: are women fairly represented? BMJ Neurol Open\u00a04(2):e000261.\u00a0https:\/\/doi.org\/10.1136\/bmjno-2021-000261","DOI":"10.1136\/bmjno-2021-000261"},{"issue":"1","key":"8135_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-021-00833-4","volume":"13","author":"M Rosende-Roca","year":"2021","unstructured":"Rosende-Roca M, Abdelnour C, Esteban E et al (2021) The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening. Alzheimers Res Ther 13(1):95. https:\/\/doi.org\/10.1186\/s13195-021-00833-4","journal-title":"Alzheimers Res Ther"},{"key":"8135_CR11","doi-asserted-by":"publisher","unstructured":"Martinkova J, Q F-C, Karcher H, Ferrari A, Sandset EC, Szoeke C, Hort J, Schmidt R, Chadha AS, Ferretti MT (2021) Proportion of women and reporting of outcomes by sex in clinical trials for Alzheimer disease: a systematic review and meta-analysis. JAMA Netw Open\u00a04(9):e2124124.\u00a0https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24124","DOI":"10.1001\/jamanetworkopen.2021.24124"},{"key":"8135_CR12","unstructured":"WHO. Clinical trials databases. https:\/\/www.who.int\/observatories\/global-observatory-on-health-research-and-development\/resources\/databases\/databases-on-processes-for-r-d\/clinical-trials. Accessed 23 Feb 2025"},{"key":"8135_CR13","unstructured":"Protocol Registration and Results System (Logo). https:\/\/register.clinicaltrials.gov\/prs\/app\/template\/ApplyOrgAccount.vm. Accessed 23 Feb 2025"},{"key":"8135_CR14","doi-asserted-by":"publisher","unstructured":"Tse T, Fain KM, Zarin DA (2018) How to avoid common problems when using Clinical Trials. gov in research: 10 issues to consider. Bmj 25;361:k1452.\u00a0https:\/\/doi.org\/10.1136\/bmj.k1452","DOI":"10.1136\/bmj.k1452"},{"key":"8135_CR15","doi-asserted-by":"publisher","unstructured":"Key MN, Shaw AR, Erickson KI, Burns JM, Vidoni ED (2024) A retrospective analysis of serious adverse events and deaths in US-based lifestyle clinical trials for cognitive health. Contemp Clin Trials Commun 38:101277.\u00a0https:\/\/doi.org\/10.1016\/j.conctc.2024.101277","DOI":"10.1016\/j.conctc.2024.101277"},{"key":"8135_CR16","doi-asserted-by":"publisher","unstructured":"Scott PEU, Ellis F et al (2018) Participation of women in clinical trials supporting FDA approval of cardiovascular drugs. JACC. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.070","DOI":"10.1016\/j.jacc.2018.02.070"},{"key":"8135_CR17","unstructured":"Association, A.s. 10 Early signs and symptoms of Alzheimer\u2019s and dementia. https:\/\/www.alz.org\/alzheimers-dementia\/10_signs. Accessed 25 Feb 2025"},{"key":"8135_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6968","author":"S Chen","year":"2022","unstructured":"Chen S, Li J, Shu M (2022) Use of participation to prevalence ratio for evaluating the representation status of women in oncology clinical trials. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.6968","journal-title":"JAMA Oncol"},{"key":"8135_CR19","unstructured":"Service, U.S.D.o.H.a.h. RaDar Rare disease registry programe. https:\/\/registries.ncats.nih.gov\/glossary\/single-group-study\/. Accessed 20 Oct 2024"},{"key":"8135_CR20","unstructured":"Service USdohah. Toolkit for patient focused therapy development. https:\/\/toolkit.ncats.nih.gov\/glossary\/parallel-study\/. Accessed 20 Oct 2024"},{"key":"8135_CR21","doi-asserted-by":"publisher","unstructured":"Lim C-Y, In J (2021) Considerations for crossover design in clinical study. Korean J Anesthesiol. https:\/\/doi.org\/10.4097\/kja.21165","DOI":"10.4097\/kja.21165"},{"key":"8135_CR22","doi-asserted-by":"publisher","unstructured":"2024 Alzheimer\u2019s disease facts and figures (2024) Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.13809","DOI":"10.1002\/alz.13809"},{"issue":"1","key":"8135_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3233\/JAD-215699","volume":"87","author":"CKL Kim","year":"2022","unstructured":"Kim CKL, Rui Yin, Ong L, Gold M, Kalali A, Sarkar J (2022) Alzheimer\u2019s disease: key insights from two decades of clinical trial failures. JAD 87(1):83\u2013100. https:\/\/doi.org\/10.3233\/JAD-215699","journal-title":"JAD"},{"key":"8135_CR24","unstructured":"trial.gov C. ClinicalTrials.gov is a place to learn about clinical studies from around the world. https:\/\/clinicaltrials.gov\/. Accessed 1 Oct 2024"},{"key":"8135_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2:349\u2013351","journal-title":"Am J Clin Dermatol"},{"key":"8135_CR26","unstructured":"USFDA. Women in Clinical Trials:Research and Policy From the FDA Office of Women\u2019s Health. https:\/\/www.fda.gov\/consumers\/diverse-women-clinical-trials\/women-clinical-trials-research-and-policy. Accessed 3 Nov 2024"},{"key":"8135_CR27","unstructured":"USFDA. Postapproval Pregnancy Safety Studies Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postapproval-pregnancy-safety-studies-guidance-industry. Accessed 3 Nov 2024"},{"key":"8135_CR28","unstructured":"USFDA. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies. Accessed 5 Nov 2024"},{"key":"8135_CR29","unstructured":"USFDA. Enhancing the Diversity of Clinical Trial Populations \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial. Accessed 17 Oct 2024"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08135-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:45:48Z","timestamp":1749530748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["8135"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08135-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}